Synthetic Biologics (NYSEAMERICAN:SYN) Trading 1% Higher – What’s Next?

Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) rose 1% on Monday . The company traded as high as $1.02 and last traded at $1.02. Approximately 57,700 shares changed hands during trading, a decline of 71% from the average daily volume of 197,338 shares. The stock had previously closed at $1.01.

Synthetic Biologics Trading Up 1.0 %

The firm has a market cap of $16.16 million, a price-to-earnings ratio of -0.84 and a beta of 1.38.

Synthetic Biologics Company Profile

Synthetic Biologics, Inc, a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases.